Related Experiment Video
Updated: May 18, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Hepatic and cardiac steatosis: are they coupled?
Elisabetta Bugianesi1, Amalia Gastaldelli
1Division of Gastro-Hepatology, Department of Internal Medicine, San Giovanni Battista Hospital, University of Turin, Corso Dogliotti 14, Turin, Italy. ebugianesi@yahoo.it
Abstract:
Cardiac and hepatic fat are associated with insulin resistance and impaired suppression of lipolysis, ultimately leading to lipotoxicity. In the heart the lipotoxic effect translates into an impairment of energetic and mechanical efficiency, whereas in the liver a fibrogenic response is favored by the abundance of inflammatory cells. These features precede, and likely contribute to, left ventricular overload and cardiac hypertrophy through mechanisms similar to the ones observed in the progression of liver damage in nonalcoholic fatty liver disease (NAFLD). Collectively these findings suggest the presence of complex and intertwined interrelationships between NAFLD, myocardial steatosis, and coronary artery disease.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cirrhosis II: Pathophysiology
Hepatic Drug Excretion: Influencing Factors
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...

